Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response. (2nd November 2019)

• Record Type: Journal Article
• Authors: Sosnowska, Anna; Czystowska-Kuzmicz, Malgorzata; Golab, Jakub
• Is Part Of: Oncoimmunology. Volume 8:Number 11(2019)
• Publication Date: 2019-11-02
• Subjects: Arginase -- extracellular vesicles -- immunotherapy -- T-cells response -- ovarian carcinoma; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2019.1655370
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Expression of arginase-1 (ARG1) is an immunosuppressive feature of tumor microenvironment that leads to depletion of ʟ-arginine, a nutrient required for T-cells expansion. Ovarian carcinoma cells release extracellular vesicles carrying enzymatically active ARG1, that contributes to local and systemic immune suppression, which can be restored by ARG inhibitor.